Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
AssigneeBoehringer Ingelheim Pharma GmbH & Co. KG
InventorsBirgit Jung, Norbert Kraut, Stefan Mueller, Barbara Kistler, Peter Seither, Karsten Quast, Andreas Weith
Life of this patent
Estimating the term…
Abstract
The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.
Claims64
A method for determining whether a substance is an activator or an inhibitor of an ILM receptor comprising:
- (a) applying the substance to a test system which generates a measurable read-out upon modulation of the ILM receptor or an ILM receptor function;
- and (b) comparing the level of the read-out of the test system to a control level, wherein a difference in levels indicates whether the substance is an activator or an inhibitor of the ILM receptor.
A method for determining an expression level of an ILM receptor comprising:
- determining the level of ILM receptor expressed in a macrophage.
A test system kit for determining whether a substance is an activator or an inhibitor of an ILM receptor function wherein the receptor is involved in a chronic inflammatory airway disease and wherein the receptor plays a role in mediating inflammation comprising at least:
- a. an ILM receptor, or
- b. an expression vector capable of expressing an ILM receptor in a cell, or
- c. a host cell transformed with an expression vector capable of expressing an ILM receptor.
A substance determined to be an activator or inhibitor of an ILM receptor.
A substance which is an activator or inhibitor of an ILM receptor for the treatment of a disease.
A pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor of an ILM receptor;
- and a pharmaceutically acceptable carrier.
A method for treating a chronic inflammatory airway disease comprising administering to a being in need of such treatment a suitable amount of a pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor of an ILM receptor.
A method for selectively modulating an ILM receptor in a macrophage comprising administering a substance determined to be an activator or inhibitor of an ILM receptor.
Dependencies are inferred from the claim text.